Total Credits: 1 including 1 AOA Category 1-A Credit(s)
Wheezing in Children. What’s New in Asthma
Identify risk factors for the development of asthma
Discuss some of the new studies on current asthma treatments.
Discuss biologics used in the treatment of asthma.
Dr. Gubernick has no actual or potential conflict of interest in relation to this program or presentation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Florida Osteopathic Medical Association (FOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
GRIEVANCE POLICY: The FOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to FOMA Executive Director Steve Winn, by calling the FOMA Office at 850-878-7364 or by mail to FOMA, 2544 Blairstone Pines Drive, Tallahassee, FL 32301, or by email to admin@foma.org
| Wheezing in Children: What's New in Asthma (3 MB) | Available after Purchase | ||
Samuel Gubernick, DO is a Pediatrics Specialist with Family Allergy, Asthma and Immunology Associates in Largo, Florida. He is a graduate of NSU-KPCOM. He completed his Pediatric Internship and Residency and his Allergy and Immunology Fellowship (Pediatric and Adult) at the University of South Florida College of Medicine. Dr. Gubernick is certified by the American Board of Allergy and Immunology and the American Board of Pediatrics. Currently, Dr. Gubernick is President of the Florida Allergy, Asthma and Immunology Society and as a Governor for the Federation of the Regional, State and Local Allergy, Asthma & Immunology Societies Assembly of the AAAAI. He has served on and chaired many statewide committees and societies and continues to present, participate and publish Allergy, Asthma & Immunology Updates.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|